Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Treatments of cold urticaria: a systematic review
|Filename||143. Kulthanan et al., Treatm. cold urt.,JACI 2019 .pdf|
|Date added||June 17, 2020|
|Tags||antihistamines, Cold urticaria, efficacy, meta-analysis, omalizumab, Safety, systematic review, treatment|
|Authors||Kulthanan, K., Hunnangkul, S.+, Tuchinda, P., Chularojanamontri, L., Weerasubpong, P., Subchookul, C., and Maurer, M.|
|Citation||Kulthanan, K., Hunnangkul, S.+, Tuchinda, P., Chularojanamontri, L., Weerasubpong, P., Subchookul, C., and Maurer, M.: Treatments of cold urticaria: a systematic review. J. Allergy Clin. Immunol. 2019: 143; 1311-1331.|
|Corresponding authors||Maurer, M.|
|Edition; Page||143; 1311-1331|
|Publisher||J. Allergy Clin. Immunol.|
Background: Several treatment options for cold urticaria (ColdU) have been studied and reported, but systematic reviews and meta-analyses are limited.
Objectives: We sought to meta-analyze and review the efficacy and safety of ColdU treatments.
Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. Suitable reports were identified by searching PubMed, Scopus, and Web of Science. Our systematic review included 16 studies, 9 of which met the eligibility criteria for the meta-analysis. We analyzed the effects of treatments on critical temperature thresholds (CTTs) and critical stimulation time thresholds (CSTTs), as well as on rates of complete response and adverse events.
Results: Our pooled meta-analyses showed that nonsedating second-generation H1-antihistamines (nsAHs) are effective in the treatment of ColdU and that updosing of nsAHs significantly reduced CTTs relative to their own standard doses and placebos. In 4 studies involving CSTTs, updosing of nsAHs also resulted in significantly better CSTTs than their own standard doses or placebos. Omalizumab resulted in a marked reduction of CTTs in H1-antihistamine–resistant patients. Of 118 adverse events in 8 studies, standard-dose nsAHs, updosed nsAHs, and omalizumab produced lower numbers of adverse events than first-generation antihistamines.
Conclusions: Our study showed that greater dosages of nsAHs were more effective than standard dosages in controlling ColdU symptoms. Increasing the dosages was not significantly associated with higher adverse event rates. Omalizumab at 150 and 300 mg every 4 weeks was shown to be effective for patients with ColdU refractory to antihistamines. (J Allergy Clin Immunol 2019;143:1311-31.)
(Last update: 08.2021)
|Number of publications (original work and reviews) in peer-reviewed journals:||636|
|Number of original publications in peer-reviewed journals:||462|
|Number of reviews in peer-reviewed journals:||174|
|Cumulative IF of publications (original work & reviews) in peer-reviewed journals:||3834,12|
|Cumulative IF for original publications in peer-reviewed journals:||3043,14|
|Cumulative IF for reviews in peer-reviewed journals:||790,98|
|Citations, Hirsch index: (view on Web of Science)||26429|